Trevi Therapeutics Inc TRVI

US Pharmaceuticals

$18.25 ▼ -0.82% ($-0.15)

📅 Earnings This Week

Open $18.49

Prev Close $18.40

Day Range $17.64 – $18.49

52W Range $6.55 – $20.22

Market Cap $2.59B

Beta 1.03

EPS (TTM) $-0.32

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-05-07
Shares Out.	141,980,000
Website	trevitherapeutics.com/ ↗
Phone	18004831140
Employees	34
Net Income	-$13.2M
Free Cash Flow	-$45.4M
Total Assets	$179.6M
Total Liabilities	$7.5M
Equity	$172.1M

About Trevi Therapeutics Inc

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Trevi Therapeutics Inc is a publicly traded company under the ticker symbol TRVI on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.